Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik

The overexpression of HER2 in breast cancer is a classic example for molecular targeted therapy, and it has been shown that classical anti-HER2 therapeutics were only effective in patients with HER2 overexpressing tumors. Therefore, in recent decades, pathologists have been focused on the reliable i...

Descripción completa

Detalles Bibliográficos
Autores principales: Denkert, Carsten, Lebeau, Annette, Schildhaus, Hans Ulrich, Jackisch, Christian, Rüschoff, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
Übersichten
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584988/
https://www.ncbi.nlm.nih.gov/pubmed/36227345
http://dx.doi.org/10.1007/s00292-022-01124-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584988/
https://www.ncbi.nlm.nih.gov/pubmed/36227345
http://dx.doi.org/10.1007/s00292-022-01124-x

Ejemplares similares